540 related articles for article (PubMed ID: 30017145)
1. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
[TBL] [Abstract][Full Text] [Related]
2. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
[TBL] [Abstract][Full Text] [Related]
4. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
7. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
[TBL] [Abstract][Full Text] [Related]
13. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
14. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
15. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
[TBL] [Abstract][Full Text] [Related]
16. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
[TBL] [Abstract][Full Text] [Related]
17. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
20. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]